Compare MakeMyTrip Ltd (MMYT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Recursion Pharmaceuticals Inc — how do they compare? MakeMyTrip Ltd trades at $49.84 (market cap $5.07B), while Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B). The key difference: MakeMyTrip Ltd is far larger — about 2.7× Recursion Pharmaceuticals Inc's market cap, and MakeMyTrip Ltd is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| MMYT | RXRX | |
|---|---|---|
Market Cap | $5.07B | $1.86B |
Sector | Technology | Health |
52-Week High | $101.86 | $6.79 |
52-Week Low | $36.30 | $2.84 |
Enterprise Value | $5.73B | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $53.90, down 3.09% today, showing technical bearish signals despite strong analyst support with 8 buy ratings. The company maintains solid revenue growth with $978M in 2025 revenue and $95M net income, though earnings volatility persists with mixed quarterly results. Recent news highlights institutional selling pressure despite positive industry outlook for internet delivery services.
Investment outlook remains cautiously optimistic given the 34% upside potential from analyst targets, but risks include declining cash flow trends and rising debt-to-asset ratios from 12% to 80% projected for 2026. The stock's high P/E ratio of 234 requires sustained earnings growth to justify valuation, making execution critical for future performance.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
